Literature DB >> 29569505

Risk factors associated with complications/sequelae of acute and subacute haematogenous osteomyelitis: an Italian multicenter study.

Elena Chiappini1, Andrzej Krzysztofiak2, Elena Bozzola2, Clara Gabiano3, Susanna Esposito4, Andrea Lo Vecchio5, Maria Rita Govoni6, Cristina Vallongo7, Icilio Dodi8, Elio Castagnola9, Nadia Rossi10, Piero Valentini11, Fabio Cardinale12, Filippo Salvini13, Gianni Bona14, Grazia Bossi15, Alma Nunzia Olivieri16, Fiorella Russo17, Emilio Fossali18, Gabriella Bottone19, Marta Dellepiane3, Maurizio De Martino1, Alberto Villani2, Luisa Galli1.   

Abstract

BACKGROUND: Acute/subacute haematogenous osteomyelitis (AHOM/SAHOM) are potentially devastating diseases. Updated information about the epidemiology, management and outcome of AHOM/SAHOM is needed to minimize the risk of complications and sequelae.
METHODS: A multicenter study was performed to evaluate retrospectively the management and outcome of AHOM/SAHOM in Italy. Data from children aged >1 month, and hospitalized between 2010 and 2016, in 19 pediatric centers, were analyzed.
RESULTS: 300 children with AHOM and 98 with SAHOM were included. Median age was 6.0 years (IQR: 2.0-11.0). No clinical difference was observed with the exception of fever at onset (63.0% vs. 42.9%; P < 0.0001), and a more common spinal involvement in SAHOM (6.7% vs 20.4%; P < 0.001). Fifty-Eight Staphylococcus aureus strains were isolated; 5 (8.6%) were MRSA. No Kingella kingae infection was documented. No different risk for complication/sequela was observed between AHOM and SAHOM (38.3% vs. 34.7%; OR:0.85; 95%CI: 0.53-1.38; P = 0.518). Duration and type of antibiotic therapy were not associated with risk of complication/sequelae.
CONCLUSION: AHOM and SAHOM displayed some differences, however occurrence and risk factors for complications and sequelae are similar, and the same empiric treatment might be recommended.

Entities:  

Keywords:  Acute haematogenous osteomyelitis; Staphylococcus aureus; children; risk factors; subacute haematogenous osteomyelitis

Mesh:

Substances:

Year:  2018        PMID: 29569505     DOI: 10.1080/14787210.2018.1453357

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  4 in total

Review 1.  Global epidemiology of childhood bone and joint infection: a systematic review.

Authors:  Sarah Hunter; Heidi Chan; Joseph F Baker
Journal:  Infection       Date:  2022-01-20       Impact factor: 3.553

2.  Nationwide epidemiologic study for pediatric osteomyelitis and septic arthritis in South Korea: A cross-sectional study of national health insurance review and assessment service.

Authors:  Jihye Kim; Min Uk Lee; Tae-Hwan Kim
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

3.  Italian consensus on the therapeutic management of uncomplicated acute hematogenous osteomyelitis in children.

Authors:  Andrzej Krzysztofiak; Elena Chiappini; Elisabetta Venturini; Livia Gargiullo; Marco Roversi; Carlotta Montagnani; Elena Bozzola; Sara Chiurchiu; Davide Vecchio; Elio Castagnola; Paolo Tomà; Gian Maria Rossolini; Renato Maria Toniolo; Susanna Esposito; Marco Cirillo; Fabio Cardinale; Andrea Novelli; Giovanni Beltrami; Claudia Tagliabue; Silvio Boero; Daniele Deriu; Sonia Bianchini; Annalisa Grandin; Samantha Bosis; Martina Ciarcià; Daniele Ciofi; Chiara Tersigni; Barbara Bortone; Giulia Trippella; Giangiacomo Nicolini; Andrea Lo Vecchio; Antonietta Giannattasio; Paola Musso; Elena Serrano; Paola Marchisio; Daniele Donà; Silvia Garazzino; Luca Pierantoni; Teresa Mazzone; Paola Bernaschi; Alessandra Ferrari; Guido Castelli Gattinara; Luisa Galli; Alberto Villani
Journal:  Ital J Pediatr       Date:  2021-08-28       Impact factor: 2.638

4.  Practical Issues in Early Switching from Intravenous to Oral Antibiotic Therapy in Children with Uncomplicated Acute Hematogenous Osteomyelitis: Results from an Italian Survey.

Authors:  Elena Chiappini; Elena Serrano; Luisa Galli; Alberto Villani; Andrzej Krzysztofiak
Journal:  Int J Environ Res Public Health       Date:  2019-09-23       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.